Review of 2025 CIRS activities
We're pleased to share a high-level summary of what CIRS got up to last year, including key research outputs and meetings. Our full 2025 Annual Report will be published [...]
Parallel Submissions in Australia and Canada – Sola-Barrado 2026
As companies navigate diverse global HTA environments, new CIRS analysis provides timely evidence on the role of parallel regulatory/HTA submissions. Our latest publication in the International Journal of Technology [...]
Examining the UK HTA Landscape for Orphan Medicines
To mark Rare Disease Day on 28 February, we’re sharing findings from our work examining how orphan new active substances (NASs) are assessed by two of the UK’s HTA [...]
Patient Involvement in Regulatory and HTA Decision Making – 2025 Workshop Report
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes.
Historical Review of the African Medicines Agency (AMA) – Ismail 2026
This journal article co-authored by CIRS, AUDA‑NEPAD, the African Medicines Agency (AMA), and University of Hertfordshire, reviews the development of the African Medicines Agency (AMA), tracing its evolution from [...]
CIRS R&D Briefing 100: Four Decades of Evidence, Insight and Impact
Explore how our R&D Briefings have impacted regulatory and health technology assessment (HTA) policy worldwide. We are delighted to share with you CIRS R&D Briefing 100, a special edition [...]
Canadian HTA landscape: Comparing HTA timelines and outcomes for CDA-AMC and INESSS
How do HTA timelines and recommendations compare across Canada’s HTA agencies? At ISPOR Europe 2025, we presented a poster analysing HTA timelines and outcomes for Canada's Drug Agency (CDA‑AMC) [...]
Patient Involvement in Regulatory and HTA Decision Making – 2025 Workshop Synopsis
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes.
HTA Submission Trends for EMA-Approved Oncology Medicines 2018-2023
How quickly do oncology medicines move from EMA approval to HTA submission across Europe — and how might this change under the EU HTA Regulation? At ISPOR Europe 2025, [...]
Q4 2025 Newsletter
We're pleased to share the latest CIRS newsletter with you, featuring updates from our recent workshops, global engagements, and research studies advancing medicine regulation and HTA. 🔍 What's Inside: [...]